Researchers Advance Quinoline CYP8B1 Inhibitor as Lead for Metabolic Disease
- CYP8B1 is a liver enzyme in the bile-acid synthesis pathway now being explored as a drug target for metabolic disorders such as nonalcoholic fatty liver disease and type 2 diabetes.
- The project started from compound 1, a CYP8B1 inhibitor identified by high-throughput screening, which broke down too quickly to be tested in live animals.
- Chemists used structure-based design and metabolite identification to learn how the molecule degraded, then ran DMPK-guided analog synthesis to explore structure-activity relationships.
- That work produced compound 9, a quinoline analog with markedly improved metabolic stability.
- In mice, compound 9 showed robust in vivo CYP8B1 inhibition, providing a validated lead for further optimization.
This is textbook DMPK-guided lead optimization done right: compound 1 degrades too fast for in vivo work, so instead of abandoning it, they identify the metabolite, figure out exactly where the molecule is falling apart, and redesign around that liability. That's the disciplined way to do hit-to-lead, and it's refreshing to see it laid out explicitly rather than glossed over. Landing on a quinoline is a plus for tractability — cheap chemistry, well-understood SAR space, easy to riff on for follow-up analogs. CYP8B1/bile-acid signaling is also a nice change of scenery from the overworked FXR and GLP-1 real estate in NAFLD/T2D. My one nagging question: going from compound 1 to a stable, in vivo-active compound 9 reads suspiciously clean for a single campaign — what substituent or ring modification actually killed the metabolic soft spot? That's the detail I'd want in the SAR table before believing this fully.